KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses (2016 - 2025)

Neogenomics' Operating Expenses history spans 16 years, with the latest figure at $96.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.15% year-over-year to $96.8 million; the TTM value through Dec 2025 reached $430.2 million, up 12.55%, while the annual FY2025 figure was $430.2 million, 12.55% up from the prior year.
  • Operating Expenses reached $96.8 million in Q4 2025 per NEO's latest filing, down from $107.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $124.9 million in Q2 2025 to a low of $56.7 million in Q1 2021.
  • Average Operating Expenses over 5 years is $90.8 million, with a median of $89.8 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 76.03% in 2021, then fell 4.16% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $86.8 million in 2021, then dropped by 4.16% to $83.2 million in 2022, then grew by 3.55% to $86.2 million in 2023, then rose by 11.02% to $95.7 million in 2024, then grew by 1.15% to $96.8 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Operating Expenses are $96.8 million (Q4 2025), $107.5 million (Q3 2025), and $124.9 million (Q2 2025).